drugset / Trial / NCT00004144
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
Phase 1
Completed
36 enrolled
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus gemcitabine in treating patients who have advanced cancer that has not responded to previous treatment.
Timeline
- Start
- 2000-05
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 800 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | bryostatin 1 | Small molecule | 25 ug/m2 | Intravenous |
| Subject | bryostatin 1 | Small molecule | 30 ug/m2 | Intravenous |
| Subject | bryostatin 1 | Small molecule | 35 ug/m2 | Intravenous |
| Subject | bryostatin 1 | Small molecule | 45 ug/m2 | Intravenous |